IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

SIENA, SALVATORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 32.738
AS - Asia 28.313
NA - Nord America 26.979
Continente sconosciuto - Info sul continente non disponibili 3.355
SA - Sud America 2.481
AF - Africa 585
OC - Oceania 460
Totale 94.911
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.270
DE - Germania 11.212
CN - Cina 11.063
GB - Regno Unito 6.784
SG - Singapore 5.427
IT - Italia 5.363
HK - Hong Kong 2.123
RU - Federazione Russa 1.985
BD - Bangladesh 1.824
BR - Brasile 1.801
VN - Vietnam 1.551
JP - Giappone 1.377
FR - Francia 1.358
IN - India 1.294
CA - Canada 1.253
SE - Svezia 1.036
KR - Corea 838
IE - Irlanda 814
FI - Finlandia 751
ES - Italia 688
NL - Olanda 682
TR - Turchia 633
ID - Indonesia 452
AU - Australia 394
TW - Taiwan 366
CH - Svizzera 248
PL - Polonia 220
AT - Austria 218
IR - Iran 213
MX - Messico 209
AR - Argentina 198
DK - Danimarca 190
RO - Romania 168
BE - Belgio 167
GR - Grecia 142
UA - Ucraina 132
CO - Colombia 130
TH - Thailandia 127
PT - Portogallo 122
IQ - Iraq 119
ZA - Sudafrica 117
EC - Ecuador 113
PK - Pakistan 113
MY - Malesia 111
PH - Filippine 108
IL - Israele 103
EU - Europa 101
NO - Norvegia 99
CL - Cile 92
CI - Costa d'Avorio 82
SA - Arabia Saudita 82
EG - Egitto 77
CZ - Repubblica Ceca 73
DZ - Algeria 65
NZ - Nuova Zelanda 65
MA - Marocco 62
JO - Giordania 60
HU - Ungheria 52
UZ - Uzbekistan 51
TN - Tunisia 46
JM - Giamaica 44
PE - Perù 44
VE - Venezuela 43
CR - Costa Rica 42
LB - Libano 41
AE - Emirati Arabi Uniti 36
KE - Kenya 32
SK - Slovacchia (Repubblica Slovacca) 29
LT - Lituania 28
RS - Serbia 28
BG - Bulgaria 25
TT - Trinidad e Tobago 24
HR - Croazia 21
NP - Nepal 21
PY - Paraguay 20
KZ - Kazakistan 19
UY - Uruguay 19
AM - Armenia 18
SC - Seychelles 18
CY - Cipro 17
GT - Guatemala 17
BO - Bolivia 16
ET - Etiopia 16
HN - Honduras 16
NG - Nigeria 16
PA - Panama 16
AZ - Azerbaigian 15
NI - Nicaragua 15
OM - Oman 15
SV - El Salvador 15
LU - Lussemburgo 14
MO - Macao, regione amministrativa speciale della Cina 14
PS - Palestinian Territory 14
SI - Slovenia 14
LK - Sri Lanka 13
PR - Porto Rico 13
BB - Barbados 12
EE - Estonia 12
AL - Albania 11
GE - Georgia 10
Totale 91.467
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 9.536
Southend 5.065
Singapore 2.878
Ashburn 2.305
Hangzhou 1.756
Hong Kong 1.622
Beijing 1.528
Milan 1.496
San Jose 1.494
Council Bluffs 1.185
Chandler 1.040
Seattle 997
Fairfield 857
Santa Clara 801
Wilmington 790
Dublin 773
Princeton 743
Shanghai 736
Los Angeles 716
Dallas 681
New York 632
Houston 630
Guangzhou 596
Redwood City 560
Nanjing 505
Helsinki 449
Tokyo 444
Woodbridge 443
Ho Chi Minh City 427
Cambridge 400
Lauterbourg 378
Rome 363
Hefei 347
Buffalo 345
Hanoi 342
Dearborn 337
Bengaluru 327
Jakarta 305
Ann Arbor 286
Moscow 281
Toronto 280
Boardman 276
Des Moines 259
Ottawa 251
Chicago 214
London 211
Phoenix 195
Columbus 193
Taipei 192
Munich 189
Tianjin 189
São Paulo 175
Jinan 174
Seoul 174
Redmond 170
Shenyang 169
Turin 165
Istanbul 154
The Dalles 149
Berlin 148
Changsha 146
Naples 141
Madrid 138
Chengdu 137
Wuhan 135
Boston 133
Dong Ket 131
Shenzhen 130
Central District 129
Nuremberg 128
Barcelona 120
San Diego 115
Vienna 111
Cangzhou 105
Amsterdam 103
Atlanta 101
Montreal 101
Bologna 100
Paris 100
Duncan 98
Zhengzhou 98
Washington 96
Mountain View 95
Nanchang 94
Hebei 92
Central 86
Mumbai 84
Abidjan 82
Melbourne 80
Chennai 78
Hyderabad 77
Manchester 76
Sakarya 76
Fuzhou 73
Regensburg 72
San Francisco 72
Hanover 70
Sydney 69
Torino 68
Falls Church 67
Totale 53.330
Salva come PNG Salva come JPEG
Nome #
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer 7.527
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer 3.557
Liquid biopsy for rectal cancer: a systematic review 1.738
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial 1.414
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy 1.301
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 1.115
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes 932
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy 878
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin 833
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer 827
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study 710
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 708
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond 708
Early-onset colorectal cancer in young individuals 686
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas 663
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies 586
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1) 578
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer 557
Increased incidence of colon cancer among individuals younger than 50 years : a 17 years analysis from the cancer registry of the municipality of Milan, Italy 494
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition 445
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression 439
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy 436
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer 430
LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion 426
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors 420
KRAS mutations testing in colorectal carcinoma patients in Italy: From guidelines to external quality assessment 419
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 417
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer 405
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 402
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer 372
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib 363
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience 346
Exploring the links between cancer and placenta development 346
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment 345
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer : a retrospective consortium analysis 328
The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer 327
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer 326
Strategies to tackle RAS-mutated metastatic colorectal cancer 325
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer 323
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial 312
Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ 311
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient 310
Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review 309
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 308
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 308
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer 307
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 298
Concurrent small cell transformation and emergence of trans-C797S and T790M mutations under sequential treatment with EGFR inhibitors in lung adenocarcinoma 297
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) 295
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer 295
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 294
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies 294
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review 292
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines 287
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) 287
Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment 284
Detection of circulating tumor DNA in early- and late-stage human malignancies 283
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 281
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery : a multicenter phase II study 279
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA 278
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 276
Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation 275
Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab 275
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 271
Platelet cryopreservation using second-messenger effector and low-dose (2%) dimethyl sulfoxide. In vitro evaluation of post-thawing platelet activity with the platelet function analyzer 269
The quest for improving treatment of cancer of unknown primary (CUP) through molecularly-driven treatments: a systematic review 266
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer : a retrospective, exploratory analysis of the CORRECT trial 263
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC) : An Italian, Multicenter, Retrospective Study 262
Circulating tumor DNA to drive treatment in metastatic colorectal cancer 260
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22) 260
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study 258
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) : a proof-of-concept, multicentre, open-label, phase 2 trial 258
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas 257
TRKA expression and NTRK1 gene copy number across solid tumours 256
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer 253
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma : results from the NEMESI study 251
Ex vivo expansion of hematopoietic cells and their clinical use 250
Adaptive mutability of colorectal cancers in response to targeted therapies 248
Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients 247
Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO) 247
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials 247
The genomic landscape of response to EGFR blockade in colorectal cancer 246
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types 245
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review 244
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : Results from two randomized first-line panitumumab studies 243
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. 242
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab 242
Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features 241
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer 241
Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature 239
Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report 238
Central Nervous System as Possible Site of Relapse in ERBB2-PositiveMetastatic Colorectal Cancer:Long-term Results of TreatmentWith Trastuzumab and Lapatinib 238
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 237
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer 236
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 233
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 233
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer 232
The evolutionary landscape of treatment for BRAFv600e mutant metastatic colorectal cancer 231
Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies 230
Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma 229
Totale 49.630
Salva come PNG Salva come JPEG
Categoria #
all - tutte 214.084
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 214.084
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.926 0 0 513 539 703 422 525 489 665 621 441 1.008
2022/20236.519 793 555 485 626 563 1.170 327 421 607 208 426 338
2023/202412.661 396 490 467 506 1.084 878 1.693 1.542 745 1.421 1.690 1.749
2024/202513.326 1.559 1.698 1.286 1.267 700 655 599 1.159 681 870 1.018 1.834
2025/202624.088 1.917 1.396 2.275 1.709 2.040 1.680 2.518 1.370 2.590 1.578 2.736 2.279
2026/20274.392 1.712 1.885 795 0 0 0 0 0 0 0 0 0
Totale 94.911